Overview

Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects

Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
To determine if treatment with HTL0009936 will lead to changes in neural activity, measured using the fMRI BOLD signal and ASL, in brain areas that are associated with spatial and working memory, learning and executive functioning.
Phase:
Phase 1
Details
Lead Sponsor:
Heptares Therapeutics Limited
Collaborator:
P1vital Limited